US2019062445A1PendingUtilityA1
Fully human antibodies against human 4-1bb
Est. expiryOct 10, 2023(expired)· nominal 20-yr term from priority
A61P 35/00A61K 39/39C07K 2317/75C07K 16/2878A61K 2039/53A61K 39/12C07K 2317/33C07K 16/30C12N 2740/15034C07K 2317/21C07K 2317/515C07K 2317/565C07K 2317/92A61K 2039/55516C07K 2317/51A61K 2039/505A61K 2300/00A61K 39/0011A61K 2039/876A61K 2039/884C07K 2317/54C07K 2317/55A61P 21/04A61P 19/02A61K 39/00C07K 16/28
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A monoclonal antibody or antigen-binding portion thereof that specifically binds to 4-1BB, comprising a light chain variable region and a heavy chain variable region, wherein:
said light chain variable region comprises a CDR1, a CDR2, and a CDR3 as depicted in FIG. 4 ; and said heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 as depicted in FIG. 3 .
2 . The monoclonal antibody or antigen-binding portion thereof of claim 1 , wherein:
said light chain comprises a variable region as depicted in FIG. 4 ; and said heavy chain comprises a variable region as depicted in FIG. 3 .
3 . A monoclonal antibody comprising a light chain and a heavy chain, wherein said light chain comprises amino acid residues 21-236 of SEQ ID NO:6 and said heavy chain comprises amino acid residues 20-467 of SEQ ID NO:3.
4 . A pharmaceutical composition comprising:
the monoclonal antibody or antigen-binding portion thereof of claim 1 ; and a pharmaceutically acceptable carrier.
5 . A pharmaceutical composition comprising:
the monoclonal antibody of claim 3 ; and a pharmaceutically acceptable carrier.
6 . A method for treating a cancer in a subject comprising administering a therapeutically effective amount of the monoclonal antibody or antigen-binding portion thereof of claim 1 to said subject.
7 . An isolated polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of amino acid residues 20-467 of SEQ ID NO:3.
8 . The polynucleotide of claim 7 that comprises the nucleotide sequence of SEQ ID NO:1.
9 . An isolated polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of amino acid residues 21-236 of SEQ ID NO:6.
10 . The polynucleotide of claim 9 that comprises the nucleotide sequence of SEQ ID NO:4.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.